CURI
CuriosityStream Inc.
CURI has a slight edge over META overall, supported by stronger fundamentals.
META
Meta Platforms, Inc.
META has lower modeled downside risk, despite its lower overall score.
CURI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CURI's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CURI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $2.86 | — |
| Current | 20x | $2.86 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
CURI has the edge over META in the historical PE scenario, which offers more potential upside but is not a forecast.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
CURI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CURI has the edge over META on the outlook, with more favorable profitability expectations.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
CURI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.24 | +75% |
| Q3 2026 | $0.14 | +$0.23 |
| Q2 2026 | $0.00 | +$0.09 |
| Q1 2026 | -$0.14 | $0.00 |
| Q4 2025 | -$0.11 | +$0.13 |
| Q3 2025 | -$0.09 | +$0.18 |
| Q2 2025 | -$0.09 | +$0.62 |
| Q1 2025 | -$0.14 | +$0.72 |
| Q4 2024 | -$0.24 | +$0.68 |
CURI has the edge over META on earnings, with more consistent year-over-year improvement.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META earned $29.32 per share over the past year, up 30% from the year before.
CURI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +13% |
| Q2 2026 | $23.2M | +22% |
| Q1 2026 | $15.2M | +0.5% |
| Q4 2025 | $19.2M | +36% |
| Q3 2025 | $18.4M | +46% |
| Q2 2025 | $19M | +53% |
| Q1 2025 | $15.1M | +26% |
| Q4 2024 | $14.1M | -4.3% |
CURI's revenue is recovering but still below its 2021 peak: $21M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +42 points |
| Q2 2026 | 39% | +37 points |
| Q1 2026 | -10% | -11 points |
| Q4 2025 | -18% | +9.9 points |
| Q3 2025 | -24% | +1.3 points |
| Q2 2025 | 2.5% | +23 points |
| Q1 2025 | 0.5% | +31 points |
| Q4 2024 | -27% | +4.8 points |
CURI's operating margin was 18% last quarter, up 42 points from the same quarter a year ago, near the top of its range since 2019.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over CURI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META has the edge over CURI on profitability, with a higher operating margin.
CURI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.4M | +0.5% |
| Q2 2026 | -$4.2M | -249% |
| Q1 2026 | $1.2M | -34% |
| Q4 2025 | $3.9M | +30% |
| Q3 2025 | $4.4M | +94% |
| Q2 2025 | $2.8M | +27% |
| Q1 2025 | $1.8M | +177% |
| Q4 2024 | $3M | +$5.6M |
CURI has the edge over META on cash flow, with more consistent year-over-year improvement.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $28.6B over the past year.
CURI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -164K shares |
| 1 year | +4.3% | +2.5M shares |
| 3 years | +14% | +7.4M shares |
| 5 years | +26% | +12.4M shares |
| Available history | +264% | +43.9M shares |
CURI has 60M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $560,000 |
| Q1 2026 | $311,000 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $33,000 |
| Q3 2024 | $192,000 |
| Q4 2020 | — |
CURI spent $871,000 buying back its own shares over the past year.
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has the edge over CURI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
CURI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
CURI has the edge over META on leverage, with a lower net debt burden relative to earnings.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META's net debt is less than a year of its operating earnings (EBITDA).
CURI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 14.3 | Oversold |
CURI's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
CURI PE vs Communication Services Sector
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
CURI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.78 | 2.9% above |
| 20 week MA | $2.75 | 4% above |
| 50 week MA | $3.07 | 6.8% below |
| 100 week MA | $3.49 | 18% below |
| 200 week MA | $2.31 | 24% above |
CURI has the edge over META on trend strength, trading above more of its moving averages.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has fallen below most of its moving averages, though it's still 21% above its 200-week average.
CURI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.90 | $13.8 | +39% |
| 2021 | $13.8 | $6.44 | -53% |
| 2022 | $6.44 | $1.17 | -82% |
| 2023 | $1.17 | $0.54 | -54% |
| 2024 | $0.54 | $1.58 | +193% |
| 2025 | $1.58 | $3.83 | +142% |
| 2026 YTD | $3.83 | $2.86 | -25% |
CURI's yearly returns have swung widely, from +193% in 2024 to −82% in 2022. It's down 25% so far in 2026.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META has the edge over CURI on returns for 2026, with the stronger performance.